国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

AstraZeneca confident to invest more in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2022-11-16 15:57
Share
Share - WeChat
Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken on May 21, 2021. [Photo/Agencies]

China's continued pursuit of high-quality economic development will foster sustainable growth of the Chinese economy, making biopharmaceutical giant AstraZeneca more confident in investing more in China, according to a senior executive of the company.

"As we look at China's role on the global stage, and in particular through this year's China International Import Expo and its opening ceremony, we have gained strong confidence in the Chinese economy," said Michael Lai, general manager of AstraZeneca China, in a recent exclusive interview with China Daily.

COVID-19 has had a worldwide impact, creating short term fluctuations. But when looking at the longer-term economic outlook of China, it's very important for AstraZeneca to continue to take China as an increasingly important global supply base, according to him.

The company has announced earlier this year its intentions to further invest in its manufacturing facilities in China, including Wuxi and Taizhou supply bases in Jiangsu province. The company is also establishing a new supply base in Qingdao, Shandong province.

According to Lai, the Qingdao investment program is part of one of the core strategies of AstraZeneca in the respiratory disease sector over the next 10 or more years, as the Qingdao supply facility will be an important base for global manufacturing, serving not just the Chinese market, but also the rest of the world.

Lai said as China pushes for high-level opening-up, the company sees a strong environment of collaboration and cooperation between global companies working in China, as well as an environment that allows Chinese companies to be able to reach out to the world.

He is also impressed by Chinese innovation.

"We are partnering with innovative Chinese companies, like Wuxi Biologics, to further expand our partnership in COVID-19 vaccines, as well neutralizing anti-bodies," he said.

"The Chinese pharmaceutical industry is at a growth phase in terms of world-class innovation. We are very excited to see a new generation of innovative biotech companies in China," he added. 

liuzhihua@chinadaily.com.cn

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
工布江达县| 临沭县| 江华| 边坝县| 武鸣县| 和龙市| 瓦房店市| 讷河市| 贵德县| 耒阳市| 辽宁省| 石泉县| 厦门市| 呈贡县| 石台县| 石屏县| 乐平市| 称多县| 长乐市| 万宁市| 鄂尔多斯市| 会宁县| 长泰县| 万州区| 新乐市| 东山县| 澄迈县| 工布江达县| 绥芬河市| 元谋县| 视频| 芜湖市| 郁南县| 高陵县| 巴马| 保定市| 沛县| 政和县| 惠来县| 宁明县| 镇安县|